This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Anwendung
Isoniazid BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.
Also used in monographs such as:
Isoniazid Oral Solution
Biochem./physiol. Wirkung
Antibiotikum für die Behandlung von Mycobacterium tuberculosis; inhibiert die Mycolsäure-Biosynthese. Wird von hepatischer N-Acetyltransferase (NAT) und Cytochrom P450 2E1 (CYP2E1) zu Hepatotoxinen metabolisert. Induziert selektiv die Expression von CYP2E1. Inhibiert Aktivitäten von CYP2C19 und CYP3A4 reversibel und inaktiviert CYP1A2, CYP2A6, CYP2C19 und CYP3A4 bei klinisch relevanten Konzentrationen.
Verpackung
Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..